Komgo – the trade finance blockchain joint venture – has successfully closed its third funding round by raising CHF 26 million. The round received a high level of interest from both new and returning investors. The investment brought
UBS Group completed its issuance of USD 750 m 3.875 per cent Tier 1 Capital Notes. The Notes are «high trigger» regulatory capital instruments that are eligible to fulfill UBS Group’s Swiss going concern requirements. The Notes
Vigier Holding entered into an agreement for the sale of Creabeton Matériaux to Müller Steinag Holding. The transaction is expected to close at the end of the first semester 2021. The legal team
Senevita took over the Sensato Group consisting of seven locations with around 200 employees. This acquisition took place in mid of May 2021 and ended on June 1st 2021. The legal team Walder Wyss acted as legal counsel
Homburger partner Daniel Häusermann (pictured) has been elected on June 1 by the Capital Markets and Technology Association (CMTA) to its Corporate Committee, which is part of the CMTA’s Advisory Board. Profile Daniel Hä
Froriep acted as legal counsel for Iconic Funds in the launch of its Iconic Funds Physical Bitcoin ETP at SIX, effective May 28, 2021. In particular, the law firm advised Iconic Funds on the entire listing process.
The insurtech startup Wefox – with its Zurich based parent company Wefox Holding (formerly FinanceApp) – has completed on 1 June a Series C financing round of 650 million USD. The legal team Walder Wyss advised the company in
Ringier Group legal department has reorganised the legal department into two core areas: Commercial IP & Technology and Corporate/M&A. These changes, effective June 2021, reflect the new requirements within the group and the
Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside
Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to
